Johnson & Johnson: Leukemia, Myeloid, Acute trials

The registry lists 14 Leukemia, Myeloid, Acute studies with Johnson & Johnson as lead sponsor. 2 are open to participants now and 2 have results posted.

Phase 1 9Phase 2 4Phase 3 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)RecruitingNCT06852222Phase 3
• A Rollover Study for Continued Study Treatment and Ongoing Safety MonitoringEnrolling by invitationNCT06788509Phase 1
• An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive ChemotherapyCompletedNCT02472145Phase 2/3Results posted
• A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT01853228Phase 1/2Results posted
• A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute LeukemiaCompletedNCT07295951Phase 1
• A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic NeoplasmsActive, not recruitingNCT06651229Phase 1
• A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic NeoplasmsActive, not recruitingNCT06618001Phase 1
• A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed TherapiesActive, not recruitingNCT05453903Phase 1
• A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT04609826Phase 1
• A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT03915379Phase 1
• Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)CompletedNCT02715011Phase 1
• A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.CompletedNCT00354146Phase 2
• Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT00093990Phase 3
• Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and OlderCompletedNCT00048503Phase 2